Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.

Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.

Major histocompatibility complex class I-related chain A (MICA) molecules are frequently expressed in lymphoproliferative malignancies including multiple myeloma (MM). MICA activates NK cells and co-stimulates T cells by interaction with its immunoreceptor NKG2D. In contrast, soluble MICA (sMICA) mo...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Rebmann, V, Schütt, P, Brandhorst, D, Opalka, B, Moritz, T, Nowrousian, MR, Grosse-Wilde, H
Format:	Journal article
Sprache:	English
Veröffentlicht:	2007

Ähnliche Einträge

The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.
von: Schütt, P, et al.
Veröffentlicht: (2008)

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
von: Schütt, P, et al.
Veröffentlicht: (2005)

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
von: Schütt, P, et al.
Veröffentlicht: (2005)

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.
von: Schütt, P, et al.
Veröffentlicht: (2006)

MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma
von: Alessandra Zingoni, et al.
Veröffentlicht: (2018-05-01)

Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification
von: Jiaxuan Xu, et al.
Veröffentlicht: (2022-10-01)

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
von: Schütt, P, et al.
Veröffentlicht: (2005)

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
von: Meletios Dimopoulos, et al.
Veröffentlicht: (2024-04-01)

Prognostic Factors Affecting Disease-Free Survival and Overall Survival in T4 Colon Cancer
von: Taeyeong Eom, et al.
Veröffentlicht: (2021-08-01)

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
von: Nowrousian, MR, et al.
Veröffentlicht: (2005)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
von: Rasmus Sørrig, et al.
Veröffentlicht: (2017-01-01)

Erratum to “Prognostic factors affecting disease-free survival and overall survival in T4 colon cancer”
Veröffentlicht: (2023-10-01)

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
von: Heinz Ludwig, et al.
Veröffentlicht: (2010-09-01)

High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
von: Shijie Zhou, et al.
Veröffentlicht: (2017-01-01)

Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients
von: Schiebel Ingrid, et al.
Veröffentlicht: (2010-12-01)

Prognostic factors for progression‐free and overall survival in malignant pleural mesothelioma
von: Jordi Guzmán‐Casta, et al.
Veröffentlicht: (2021-04-01)

Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
von: Jiayi Li, et al.
Veröffentlicht: (2022-10-01)

Correction: High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
von: Shijie Zhou, et al.
Veröffentlicht: (2018-01-01)

Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT
von: Christine M. Ho, et al.
Veröffentlicht: (2017-06-01)

The prognostic value of preoperative D-dimer to albumin ratio for overall survival and progression-free survival in colorectal cancer
von: Lishuang Wei, et al.
Veröffentlicht: (2024-02-01)

Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma.
von: Vinod Kumar, et al.
Veröffentlicht: (2012-01-01)

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
von: Evangelos Terpos, et al.
Veröffentlicht: (2009-03-01)

CGB5 expression is independently associated with poor overall survival and recurrence‐free survival in patients with advanced gastric cancer
von: Yuxin Yang, et al.
Veröffentlicht: (2018-03-01)

The prognostic nutritional index, an independent predictor of overall survival for newly diagnosed follicular lymphoma in China
von: Jingjing Ge, et al.
Veröffentlicht: (2022-10-01)

Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer
von: Hailun Xie, et al.
Veröffentlicht: (2023-02-01)

Prognostic Value of Preoperative Serum Carcinoembryonic Antigen for Overall Survival and Recurrence-Free Survival in Resectable Thymic Epithelial Tumors
von: Yang-Yu Huang MD, et al.
Veröffentlicht: (2022-10-01)

SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE
von: Stergios Intzes, et al.
Veröffentlicht: (2021-01-01)

Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer
von: Patrick McGarrah MD, et al.
Veröffentlicht: (2023-06-01)

Effects of BMI on prognosis, disease-free survival and overall survival of breast cancer
von: Vahid Zangouri, et al.
Veröffentlicht: (2025-02-01)

Improved estimation of overall survival and progression-free survival for state transition modeling
von: Peter C Wigfield, et al.
Veröffentlicht: (2023-12-01)

Prognostic nomograms to predict overall survival and cancer‐specific survival in patients with pelvic chondrosarcoma
von: Li Chen, et al.
Veröffentlicht: (2019-09-01)

THE EFFECT OF BISPHOSPHONATE USE ON TREATMENT RESPONSE AND OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS
von: Ayşe Uysal, et al.
Veröffentlicht: (2021-11-01)

Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas
von: Lisa Millgård Sagberg, et al.
Veröffentlicht: (2024-10-01)

Fractal characteristics of May-Grünwald-Giemsa stained chromatin are independent prognostic factors for survival in multiple myeloma.
von: Daniela P Ferro, et al.
Veröffentlicht: (2011-01-01)

Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities
von: Shuangshuang Jia, et al.
Veröffentlicht: (2022-03-01)

Prognostic factors affecting overall survival in right colon cancer
von: Mehmet Ince, et al.
Veröffentlicht: (2017-03-01)

Establishing nomograms for predicting disease-free survival and overall survival in patients with breast cancer
von: Ling Zhou, et al.
Veröffentlicht: (2024-12-01)

The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen
von: Yanbin Pang, et al.
Veröffentlicht: (2020-09-01)

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
von: Apostolia-Maria Tsimberidou, et al.
Veröffentlicht: (2019-12-01)

Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single center, real-world experience
von: Ke Xu, et al.
Veröffentlicht: (2024-12-01)